Physicians

Department / Division
Medicine / Medicine-Neurology

Address
DUMC 3333
Durham, NC 27710

Appointment Telephone
919-668-7600

Office Telephone
919-668-2493

Fax Telephone
919-681-4935

Training

• MD, University of Miami Leonard M. Miller School of Medicine (Florida), 1990

Residency

• Neurology, Duke University Medical Center, 1991-1994

Fellowship

• Movement Disorders, Baylor College of Medicine (Texas), 1994-1995

Other Training

• PhD, Anatomy, Duke University, 1984

Clinical Interests
Movement disorders, Parkinson's disease, Parkinson's-plus syndromes, chorea, dystonia, tics, Tourette's syndrome, tremors, tardive dyskinesia, Huntington's disease, myoclonus, botulinum toxin injections, restless legs syndrome, Wilson's disease

Research Interests
I am a Movement Disorders Neurologist and see patients at the Morreene Rd Clinic and at the Durham VA Medical Center.
Among the types of movement disorders patients that I see in clinic are individuals who have Parkinson's disease, Essential Tremor, tics, chorea, dystonia, Huntington's disease, tardive movement disorders and Wilson's disease.  I use botulinum toxin injections to treat selected patients afflicted with dystonia, tremors, and tics. I manage patients who have undergone deep brain stimulation (DBS) for the treatment of Parkinson's disease, Essential Tremor,and dystonia. In addition to managing patients who have movement disorders, I participate in a variety of clinical trials focussed on improving the management and treatment of Parkinson's disease, Huntington's disease, and dystonia.

Key words: movement disorders, Parkinson's disease, tremors, tics, chorea, dystonia, botulinum toxin injections.

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Allergan, Inc.
• GE Healthcare
• Lundbeck

Representative Publications
Scott BL (2000): Evaluation and treatment of dystonia. CME article of the month. Southern Med J 93:746-751 (2000)

1. Scott WK, Yamaoka LH, Stajich JM, Scott BL, Watts RL, Nance M, Hubble J, Koller W, Stern MB, Colcher A, Allen Jr FH, Hiner BC, Jankovic J, Ondo W, Laing NG, Mastaglia F, Goetz C, Pappert E, Small GW, Masterman D, Haines JL, Davis TL, Vance JM, Roses AD, Pericak-Vance MA (1999): The a-synuclein gene is not a major risk factor in familial Parkinson Disease.  Neurogenetics 2:191-192. (1999)

Scott BL, Welch K, deSerrano V, Moss NC, Roses AD, Strittmatter WJ (1998). Human apolipoprotein E accelerates microtubule polymerization in vitro. Neurosci Lett 245:105-108. (1998)

Scott BL, Evans RW, Jankovic J (1996). Treatment of palatal myoclonus with sumatriptan. Mov Disord 11:748-752. (1996)

Scott BL, Jankovic J (1996). Delayed-onset progressive movement disorders after static brain lesions. Neurology 46:68-74. (1996)

Scott BL, Jankovic J, Donovan DT (1996). Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette’s syndrome. Mov Disord 11:431-433. (1996)

Turner DA, Scott BL, Johnson PB, Gorecki J (1996).  Resurgence of stereotaxic procedures for relief of parkinsonism:  Role of image-directed targeting and current status.  NC Med J 57:320-324. (1996)

Scott BL, Bazan NG (1989). Membrane docosahexaenoate is supplied to the developing brain and retina by the liver. Proc Natl Acad Sci USA 86:2903-2907. (1989)

Corless JM, McCaslin DR, Scott BL (1982). Two-dimensional rhodopsin crystals from disk membranes of frog retinal rod outer segments. Proc Natl Acad Sci USA 79:1116-1120. (1982)